Clinical Trials Logo

Inflammation clinical trials

View clinical trials related to Inflammation.

Filter by:

NCT ID: NCT01057615 Completed - Asthma Clinical Trials

Effect of Fish Oil and Vitamin C on Exercise-Induced Bronchoconstriction and Airway Inflammation in Asthma

Start date: March 2010
Phase: Phase 1
Study type: Interventional

Combining fish oil and vitamin C supplementation will provide a greater anti-inflammatory effect against developing exercise-induced bronchoconstriction (EIB) than either nutritional supplement alone.

NCT ID: NCT01055249 Completed - Pain Clinical Trials

UVB Model Validation Study

Start date: January 2010
Phase: Phase 1
Study type: Interventional

Single centre, subject and observer blinded, placebo controlled, cross-over study of the effect of oral ibuprofen and topical hydrocortisone-21-acetate on ultraviolet radiation (UVR) induced pain and inflammation in healthy volunteers conducted in two segments and using an intra-individual comparison of application areas.

NCT ID: NCT01054989 Completed - Clinical trials for Healthy Adults With Normal BMI

Fat, Inflammation and Insulin Resistance

FIRE
Start date: March 15, 2009
Phase: Phase 4
Study type: Interventional

The combination of impaired insulin sensitivity and insulin secretion is thought to be the basis of type 2 diabetes. Increased free fatty acids levels impair insulin action in muscle and liver, but also systemic inflammation processes play a role in the development of insulin resistance. This study compares the effects of fat and inflammation on insulin sensitivity, systemic inflammation, energy metabolism, vascular system and neural function in healthy humans.

NCT ID: NCT01054768 Completed - Anemia, Sickle Cell Clinical Trials

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.

NCT ID: NCT01053234 Completed - Type 2 Diabetes Clinical Trials

Different Insulin Regimens and Postprandial Coagulation Activation

Start date: February 2007
Phase: N/A
Study type: Interventional

The purpose of this study in patients with type 2 diabetes was to investigate the acute effect of postprandial blood glucose levels modified by two different insulin treatment regimens on coagulation activation, inflammation and endothelial cell function. The investigators hypothesized that the rapid-acting insulin analogue aspart has a beneficial postprandial effect on coagulation, endothelial dysfunction and inflammation compared with the intermediate-acting insulin NPH due to its ability to lower postprandial glycaemia.

NCT ID: NCT01049295 Recruiting - Breast Cancer Clinical Trials

Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The aim of this study is to assess the effects of n-3 fatty acids on taxane-induced neuropathy and neurotoxic inflammatory agents in patients suffering from invasive breast cancer.

NCT ID: NCT01048593 Terminated - Clinical trials for Inflammatory Reaction Due to Ocular Lens Prosthesis

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Start date: January 2010
Phase: Phase 2
Study type: Interventional

This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.

NCT ID: NCT01047280 Completed - Inflammation Clinical Trials

Use of Conjugated Linoleic Acid as a Nutraceutical for Weight Loss in Humans

CLA
Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of the study is to examine how a naturally occurring fat found in meats, such as beef and lamb and milk, called conjugated linoleic acid (CLA), will affect your body weight and body fat content, blood fat levels, as well as selected safety parameters. The CLA will be supplemented in an oil form and will be added to solid foods as provided by the metabolic kitchen at the Richardson Centre for Functional Foods and Nutraceuticals (RCFFN).

NCT ID: NCT01046682 Completed - HIV Clinical Trials

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

Salsalate
Start date: January 2009
Phase: Phase 2
Study type: Interventional

This is a phase II, open label, randomized-controlled pilot study designed to study both the efficacy and safety of salsalate in decreasing endothelial cell dysfunction, systemic inflammation, and insulin resistance in HIV-infected adults. The investigators hypothesis is that salsalate will reduce inflammation and therefore endothelial cell activation and insulin resistance. The sample size will be 40, with an equal number of people being randomized to one of two groups. The first arm will be randomized to salsalate therapy. The second arm will act as a control group. The study duration will be 13 weeks.

NCT ID: NCT01046604 Active, not recruiting - Clinical trials for Mitral Valve Regurgitation

Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery

Start date: January 2010
Phase: Phase 4
Study type: Interventional

In the absence of treatment, severe mitral valve regurgitation (MR) results in left atrium (LA) dilatation and hypertrophy, followed ultimately by left ventricular dysfunction and heart failure. One promising intervention for the prevention of the deleterious effects of pressure overload-induced cardiac hypertrophy and heart failure is dietary supplementation with n-3 polyunsaturated fatty acids (PUFAs). However, the molecular targets and mechanisms by which n-3 PUFAs exert their effects are not completely defined. A possible target of n-3 PUFAs is the mitochondrial membrane which has broad implications given that mitochondrial dysfunction and altered metabolism have been associated with cardiac hypertrophy and heart failure. The investigators have recently identified significant mitochondrial dysfunction in the LA of patients with severe MR, as compared to their non-hypertrophied right atrium (RA). However, the investigators have not addressed the possibility that intervention with purified n-3 PUFAs (Lovaza) could improve mitochondrial function. From a mechanistic perspective, the investigators have observed in vitro that n-3 PUFAs accumulate predominately into the mitochondrial membrane of cardiomyocytes where the investigators believe they exert their effects on the biophysical organization of the membrane. Therefore, the CENTRAL HYPOTHESIS is that administering Lovaza to patients with severe MR will reduce apoptosis and improve mitochondrial function in LA (Aim 1). This change in mitochondrial function will be driven by significant biochemical and biophysical remodeling of the mitochondrial membrane (Aim 2).